Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
17.05
-1.05 (-5.80%)
At close: Sep 17, 2025, 4:00 PM EDT
17.29
+0.24 (1.40%)
After-hours: Sep 17, 2025, 7:59 PM EDT
Sarepta Therapeutics Employees
Sarepta Therapeutics had 1,372 employees as of December 31, 2024. The number of employees increased by 58 or 4.41% compared to the previous year.
Employees
1,372
Change (1Y)
58
Growth (1Y)
4.41%
Revenue / Employee
$1,808,696
Profits / Employee
-$42,242
Market Cap
1.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,372 | 58 | 4.41% |
Dec 31, 2023 | 1,314 | 152 | 13.08% |
Dec 31, 2022 | 1,162 | 322 | 38.33% |
Dec 31, 2021 | 840 | -26 | -3.00% |
Dec 31, 2020 | 866 | 123 | 16.55% |
Dec 31, 2019 | 743 | 244 | 48.90% |
Dec 31, 2018 | 499 | 244 | 95.69% |
Dec 31, 2017 | 255 | 58 | 29.44% |
Dec 31, 2016 | 197 | -73 | -27.04% |
Dec 31, 2015 | 270 | 66 | 32.35% |
Dec 31, 2014 | 204 | 58 | 39.73% |
Dec 31, 2013 | 146 | 43 | 41.75% |
Dec 31, 2012 | 103 | 5 | 5.10% |
Dec 31, 2011 | 98 | 0 | - |
Dec 31, 2010 | 98 | 35 | 55.56% |
Dec 31, 2009 | 63 | -20 | -24.10% |
Dec 31, 2008 | 83 | -42 | -33.60% |
Dec 31, 2007 | 125 | 8 | 6.84% |
Dec 31, 2006 | 117 | -6 | -4.88% |
Dec 31, 2005 | 123 | 11 | 9.82% |
Dec 31, 2004 | 112 | 6 | 5.66% |
Dec 31, 2003 | 106 | 17 | 19.10% |
Dec 31, 2002 | 89 | 4 | 4.71% |
Dec 31, 2001 | 85 | 14 | 19.72% |
Dec 31, 2000 | 71 | 15 | 26.79% |
Dec 31, 1999 | 56 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SRPT News
- 12 days ago - Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year - Business Wire
- 20 days ago - mRNA Biotechs - Long-Term Value Risks Abound - Seeking Alpha
- 23 days ago - SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT - PRNewsWire
- 25 days ago - SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT) - GlobeNewsWire
- 26 days ago - Sarepta Therapeutics: A Strong Opportunity Amidst The Panic - Seeking Alpha
- 26 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - PRNewsWire
- 27 days ago - Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027 - Business Wire
- 4 weeks ago - SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline - GlobeNewsWire